Biomarkers of neurodegeneration play a major role in the diagnosis of Alzheimer’s disease (AD). Information on both amyloid-β accumulation, e.g., from amyloid positron emission tomography (PET), and downstream neuronal injury, e.g., from 18F-fluorodeoxyglucose (FDG) PET, would ideally be obtained in a single procedure.
Objective:
On the basis that the parallelism between brain perfusion and glucose metabolism is well documented, the objective of this work is to evaluate whether brain perfusion estimated in a dual-point protocol of 18F-florbetaben (FBB) PET can be a surrogate of FDG PET in appropriate use criteria (AUC) for amyloid PET.
Methods:
This study included 47 patients fulfilling international AUC for amyloid PET. FDG PET, early FBB (pFBB) PET (0–10 min post injection), and standard FBB (sFBB) PET (90–110 min post injection) scans were acquired. Results of clinical subjective reports and of quantitative region of interest (ROI)-based analyses were compared between procedures using statistical techniques such as Pearson’s correlation coefficients and t-tests.
Results:
pFBB and FDG visual reports on the 47 patients showed good agreement (k > 0.74); ROI quantitative analysis indicated that both data modalities are highly correlated; and the t-test analysis does not reject the null hypothesis that data from pFBB and FDG examinations comes from independent random samples from normal distributions with equal means and variances.
Conclusions:
A good agreement was found between pFBB and FDG data as obtained by subjective visual and quantitative analyses. Dual-point FBB PET scans could offer complementary information (similar to that from FDG PET and FBB PET) in a single procedure, considering pFBB as a surrogate of FDG.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement7, 270–279.
TiepoltS, HesseS, PattM, LuthardtJ, SchroeterML, HoffmannK-T, WeiseD, GertzH-J, SabriO, BarthelH (2016) Early 18F-florbetaben and 11C-PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease, Eur J Nucl Med Mol Imaging43, 1700–1709.
13.
BullichS, BarthelH, KoglinN, BeckerGA, SantiSD, JovalekicA, StephensAW, SabriO (2018) Validation of non-invasive tracer kinetic analysis of 18F-Florbetaben PET using a dual time-window acquisition protocol, J Nucl Med59, 1104–1110.
14.
BeckerGA, IchiseM, BarthelH, LuthardtJ, PattM, SeeseA, Schultze-MosgauM, RohdeB, GertzH-J, ReiningerC, SabriO (2013) PET quantification of 18F-Florbetaben binding to β-amyloid deposits in human brains, J Nucl Med54, 723–731.
GaribottoV, MorbelliS, PaganiM (2016) Dual-phase amyloid PET: Hitting two birds with one stone, Eur J Nucl Med Mol Imaging43, 1300–1303.
17.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, HedrickS, PappasV, CarrilloMC, HartleyDM (2013) Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education, J Nucl Med54, 1011–1013.
18.
ArbizuJ, García-RibasG, CarrióI, GarrastachuP, Martínez-LageP, MolinuevoJL (2015) Recomendaciones para la utilización de biomarcadores de imagen PET en el proceso diagnóstico de las enfermedades neurodegenerativas que cursan con demencia: Documento de consenso SEMNIM y SEN, Rev Esp Med Nucl Imagen Mol34, 303–313.
19.
RabinoviciGD, KarlawishJ, KnopmanD, SnyderHM, SperlingR, CarrilloMC (2016) Testing and disclosures related to amyloid imaging and Alzheimer’s disease: Common questions and fact sheet summary, Alzheimers Dement12, 510–515.
20.
Carnero PardoC (2007) Utilidad diagnóstica del Test de las Fotos (Fototest) en el deterioro cognitivo y demencia. Neurología22, 860–869.
21.
VarroneA, AsenbaumS, BorghtTV, BooijJ, NobiliF, NågrenK, DarcourtJ, KapucuÖL, TatschK, BartensteinP, LaereKV (2009) EANM procedure guidelines for PET brain imaging using 18F-FDG, version 2, Eur J Nucl Med Mol Imaging36, 2103.
Salas-GonzalezD, GórrizJM, RamírezJ, IllánIA, LangEW (2013) Linear intensity normalization of FP-CIT SPECT brain images using the α-stable distribution, Neuroimage65, 449–455.
26.
BullichS, VillemagneVL, CatafauAM, JovalekicA, KoglinN, RoweCC, De SantiS (2017) Optimal reference region to measure longitudinal amyloid-beta change with 18F-Florbetaben PET, J Nucl Med58, 1300–1306.
27.
MinoshimaS, DrzezgaAE, BarthelH, BohnenN, DjekidelM, LewisDH, MathisCA, McConathyJ, NordbergA, SabriO, SeibylJP, StokesMK, LaereKV (2016) SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0, J Nucl Med57, 1316–1322.
28.
MorbelliS, BrugnoloA, BossertI, BuschiazzoA, FrisoniGB, GalluzziS, BerckelV, N.mB, OssenkoppeleR, PerneczkyR, DrzezgaA, DidicM, GuedjE, SambucetiG, BottoniG, ArnaldiD, PiccoA, De CarliF, PaganiM, NobiliF (2015) Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: An European Alzheimer’s Disease Consortium (EADC) Project, J Alzheimers Dis44, 815–826.
29.
Tzourio-MazoyerN, LandeauB, PapathanassiouD, CrivelloF, EtardO, DelcroixN, MazoyerB, JoliotM (2002) Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, Neuroimage15, 273–289.
AltmanDG, BlandJM (1983) Measurement in medicine: The analysis of method comparison studies, J R Stat Soc Series D Stat32, 307–317.
33.
Rodriguez-VieitezE, LeuzyA, ChiotisK, Saint-AubertL, WallA, NordbergA (2017) Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease, J Cereb Blood Flow Metab37, 740–749.
34.
LinK-J, HsiaoI-T, HsuJ-L, HuangC-C, HuangK-L, HsiehC-J, WeyS-P, YenT-C (2016) Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment, Eur J Nucl Med Mol Imaging43, 1304–1314.
35.
ForsbergA, EnglerH, BlomquistG, LångströmB, NordbergA (2012) The use of PIB-PET as a dual pathological and functional biomarker in AD, Biochim Biophys Acta1822, 380–385.
36.
GurRC, RaglandJD, ReivichM, GreenbergJH, AlaviA, GurRE (2009) Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state, Cereb Cortex19, 375–382.
37.
WongCO, ThieJ, GaskillM, PontoR, HillJ, TianH, BalonH, WuD, Fink-BennettD, NagleC (2006) A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging, BMC Nucl Med6, 4.
38.
SilvermanDHS (2004) Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging, J Nucl Med45, 594–607.
39.
RostomianAH, MadisonC, RabinoviciGD, JagustWJ (2011) Early 11C-PIB frames and 18F-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients, J Nucl Med52, 173–179.
40.
KnopmanDS, DeKoskyST, CummingsJL, ChuiH, Corey-BloomJ, RelkinN, SmallGW, MillerB, StevensJC (2001) Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology56, 1143–1153.
41.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
42.
FuL, LiuL, ZhangJ, XuB, FanY, TianJ (2014) Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis, Eur Radiol24, 2800–2809.
MattssonN, TosunD, InselPS, SimonsonA, JackCR, BeckettLA, DonohueM, JagustW, SchuffN, WeinerMW (2014) Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment, Brain137, 1550–1561.
